Zealand Pharma’s Obesity Drug Faces Setback in Mid-Stage Trial

Shares in Zealand Pharma fell sharply on Friday, March 6, 2026, after its obesity drug candidate, petrelintide, developed in collaboration with Roche, showed disappointing results in a phase 2 clinical trial. The setback impacts both companies’ efforts to compete in the rapidly growing obesity treatment market.

Trial Results and Market Reaction

Zealand Pharma’s stock price plummeted 34% in Copenhagen following the release of the trial data. Despite meeting its primary target and exhibiting a side-effect profile comparable to a placebo, patients treated with petrelintide achieved an average weight loss of 10.7% after 42 weeks. This result fell short of expectations, wiping billions of Danish krone off Zealand’s market capitalization. Roche’s shares too experienced a decline, falling over 3% in morning trading in Zurich.

Competitive Landscape and Analyst Views

The disappointing results are particularly notable given the intense competition in the obesity treatment market, currently dominated by Novo Nordisk and Eli Lilly. Analysts at Barclays described the data as “disappointing” because the 10.7% weight reduction was below the 13% threshold considered necessary for competitive efficacy.

Roche and Zealand Pharma initially entered into a licensing agreement in 2024, with Roche paying up to $5.3 billion to Zealand if all milestones were met.

Drug Mechanisms and Future Outlook

Petrelintide works by mimicking the effects of the amylin hormone, which promotes feelings of fullness. This differs from the mechanism of action of leading obesity drugs like Novo Nordisk’s Wegovy and Ozempic, and Eli Lilly’s Mounjaro and Zepbound, which are based on the gut hormone GLP-1 and suppress appetite. Lilly’s amylin competitor, eloralintide, demonstrated a weight loss of up to 20.1% in a phase 2 trial.

If petrelintide progresses to a phase 3 trial and receives regulatory approval, it is not expected to be available on the market until 2029.

Key Takeaways

• Zealand Pharma’s petrelintide showed modest weight loss in a phase 2 trial, leading to a significant drop in the company’s stock price.
• The results highlight the challenges of competing with established obesity treatments from Novo Nordisk and Eli Lilly.
• Petrelintide’s development timeline extends to at least 2029, contingent on successful phase 3 trials and regulatory approval.